cannabinoid

Stanford Researchers Open Medical Cannabis Company with Oral Therapy for MS Pain, Spasticity as Initial Goal

A new medical cannabis company calledĀ Katexco PharmaceuticalsĀ aims to develop oral therapies that harness the brain’s endocannabinoid and nicotine receptors to treat inflammatory diseases such as multiple sclerosis. Co-founded by two Stanford University researchers ā€” Jonathan Rothbard, PhD, and Lawrence Steinman, MD ā€” Katexco will leverage their expertise…

Holland Approves Clinical Trial Plans for AXIM’s Cannabis-based Gum for MS Pain and Spasticity

Dutch regulators have signed off onĀ AXIM Biotechnologies’Ā clinical trial plans forĀ a chewing gum that offers controlled release of cannabinoids to treat multiple sclerosis patients’ pain and spasticity. The Dutch Medicines Evaluation Board’s sign-off on MedChew Rx means AXIM can start trials. A leader in cannabinoid research, New York-based AXIM…

AXIM Moving Ahead with Testing of Cannabinoid Products, Including Chewing Gum for MS Patients

AXIM Biotechnologies Ā announced it has secured financing from private sources to continue its testing of medicalĀ cannabinoid products as potential treatments forĀ multiple indications, includingĀ pain and spasticity in people with multiple sclerosis (MS). Specifically, AXIM Ā is testing pharmaceutical delivery systems andĀ active ingredients for itsĀ medical marijuana line. ā€œThis financing provides us with…

Could Multiple Sclerosis Sufferers Benefit From Cannabis Chewing Gum?

AXIM Biotechnologies, Inc., a biotechnology company focused on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products derived from industrial hemp, has announced commencement of clinical development of its leading patented pharmaceutical chewing gum, MedChew RX, for registration as a drug for relieving pain and/or spasticity…